Literature DB >> 7452078

Cobalamin binding and uptake in vitro in the human central nervous system.

G S Lazar, R Carmel.   

Abstract

Little information exists about the CNS transport of cobalamin. Therefore we undertook to characterize the cobalamin-binding proteins of CSF and to examine uptake of the vitamin by homogenates of CNS tissue. CSF from 24 patients had a mean unsaturated cobalamin-binding capacity of 335 +/- 282 pg/ml. The vast majority of this was TC II (302 +/- 276 pg/ml). The remainder consisted of R binder and a binder eluting with the void volume on Sephadex G-200 gel chromatography. CSF TC II was identical to serum TC II immunologically, functionally, in molecular size, and in electrophoretic mobility, but the levels of the two did not correlate. CSF TC II levels may correlate best with CSF protein levels and tended to be higher in abnormal fluids. Unlike serum TC II, CSF TC II tended to adhere to glass surfaces; uncorrected, this may be a source of artifact in studying various fluids. CSF contains little cobalamin, but most of the endogenous cobalamin was carried by TC II instead of by R binder. Thus CSF appears to have a much higher total TC II: R binder ratio than does plasma. TC II enhanced 57CoB12 uptake by neonatal and adult human brain homogenate and by mouse brain homogenate. The primary phase of TC II-57CoB12 uptake in vitro by human brain cortex homogenate occurred mostly within 30 min and was maximal at 22 degrees C. Uptake was specific, but apo-and holo-TC II appeared to have equal affinity for the receptors. Spinal cord homogenate took up less TC II-57CoB12 per wet weight of tissue than did brain homogenate. R binders did not enhance cobalamin uptake; in fact, they inhibited it. We conclude that uptake of cobalamin by CNS tissue is dependent on TC II and that TC II may be even more prominent in cobalamin transport in the CSF than it is in plasma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7452078

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

Review 1.  Multiple sclerosis and vitamin B12 metabolism.

Authors:  E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

2.  Maternofetal transport of vitamin B12: role of TCblR/CD320 and megalin.

Authors:  Kaveri Arora; Jeffrey M Sequeira; Edward V Quadros
Journal:  FASEB J       Date:  2017-03-28       Impact factor: 5.191

3.  Transcobalamin II in human seminal plasma.

Authors:  R Carmel; G S Bernstein
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

4.  Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone.

Authors:  S T Frequin; R A Wevers; M Braam; F Barkhof; O R Hommes
Journal:  J Neurol       Date:  1993-05       Impact factor: 4.849

5.  Gastric juice in congenital pernicious anemia contains no immunoreactive intrinsic factor molecule: study of three kindreds with variable ages at presentation, including a patient first diagnosed in adulthood.

Authors:  R Carmel
Journal:  Am J Hum Genet       Date:  1983-01       Impact factor: 11.025

6.  Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia.

Authors:  T Q Nijst; R A Wevers; H C Schoonderwaldt; O R Hommes; A F de Haan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

Review 7.  Genetic patterns of transcobalamin II and the relationships with congenital defects.

Authors:  M Fràter-Schröder
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

8.  Vitamin B12 conjugation of peptide-YY(3-36) decreases food intake compared to native peptide-YY(3-36) upon subcutaneous administration in male rats.

Authors:  Kelly E Henry; Clinton T Elfers; Rachael M Burke; Oleg G Chepurny; George G Holz; James E Blevins; Christian L Roth; Robert P Doyle
Journal:  Endocrinology       Date:  2015-02-06       Impact factor: 4.736

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.